Your browser doesn't support javascript.
loading
Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma.
Wei, Daoyan; Chen, Dongmei; Mou, Hongyuan; Chakraborty, Sharmistha; Wei, Bo; Tan, Lin; Lorenzi, Philip L; Qian, Xiangping; Yang, Peiying.
Affiliation
  • Wei D; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Chen D; Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mou H; NeuPharma, San Mateo, California.
  • Chakraborty S; Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wei B; Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tan L; Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lorenzi PL; Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Qian X; NeuPharma, San Mateo, California.
  • Yang P; Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mol Cancer Ther ; 22(6): 693-705, 2023 06 01.
Article de En | MEDLINE | ID: mdl-36780187

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome hépatocellulaire / Tumeurs du foie Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Mol Cancer Ther Sujet du journal: ANTINEOPLASICOS Année: 2023 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome hépatocellulaire / Tumeurs du foie Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Mol Cancer Ther Sujet du journal: ANTINEOPLASICOS Année: 2023 Type de document: Article Pays de publication: États-Unis d'Amérique